Humacyte
HUMA on Nasdaq. Humacyte sells human blood vessels grown from donor cells to hospitals and surgeons. Market value $155m.
Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
Read the warning sign in its own filings
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-71.66 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: 20 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$0.44 a share, 32% above its 1-year low
Over the past year the price has ranged from $0.34 to $1.52.
Pays no dividend
Prices from Friday’s close (20 November).
Five years of cash, in billions
| Revenue | |||||
| Revenue | n/a | n/a | n/a | $0 | $2m |
| Operating margin | |||||
| Operating margin | n/a | n/a | n/a | n/a | -5306.0% |
| Debt to equity | |||||
| Debt to equity | 0.43 | n/a | n/a | n/a | 20.86 |
| Shares outstanding | |||||
| Shares outstanding | 0.10bn | 0.10bn | 0.13bn | 0.19bn | 0.28bn |
Health checks
- Free cash flow positive0 of 5 years
- Accounting checksSkipped: company is not yet profitable
- Debt20.86× equity
- Revenue growth, five yearsUnknown
- Buying back its own sharesNo, 169% more shares since 2021
The quarter to September 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $1 million last quarter, up 37% on a year ago.
- A loss of $16 million, compared with a loss of $18 million a year ago.
- It loses 4603 cents on each $1 of sales, compared with 6708 cents a year earlier.
- Over the past 12 months it spent $89 million more cash than it brought in, compared with $106 million a year earlier.
- 75% more shares than a year ago. Each share owns a bit less of the company.
- Sales grew on a year ago in 3 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| December 2024 | $0 |
| March 2025 | $517,000 |
| June 2025 | $301,000 |
| September 2025 | $753,000 |
| December 2025 | $467,000 |
| March 2026 | $495,000 |
| June 2026 | $406,000 |
| September 2026 | $1m |
| Quarter to | Amount |
|---|---|
| December 2024 | -$21m |
| March 2025 | $39m |
| June 2025 | -$38m |
| September 2025 | -$18m |
| December 2025 | -$25m |
| March 2026 | -$18m |
| June 2026 | -$37m |
| September 2026 | -$16m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 27 March 2026
- Next quarterly (estimated, 10-Q)
- 9 February 2027
Who owns it
1 long-term investor we follow owns it, unchanged from 1 last quarter. 162 funds in all.
- Letko BrosseauLetko Brosseau team
- Value
- $35,859
- Share of fund
- <0.1%
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Letko BrosseauLetko Brosseau team | $35,859 | <0.1% |
Largest holders overall
- Antipodes Partners$8mAdded
- Vanguard Capital Management$8mAdded
- Alyeska Investment Group, L.P.$5mNew
- Davidson Kempner Capital Management LP$4mNew
- BlackRock$4mCut
- Great Point Partners$3m
- UBS Group AG$2mAdded
- AQR Capital Management$2mAdded
- Geode Capital Management$2mCut
- Millennium Management$1mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
2 investors own more than 5%.
- Fresenius Medical Care Holdings, Inc.at least 4.9%−1.9 pts(filed with 1 related holder)Since 14 August 2026
- Davidson Kempner Capital Management LPPassive investorat least 4.7%(filed with 3 related holders)Since 12 June 2026
- BlackRock, Inc.Passive investorSold down below 5%Since 30 June 2026
| Holder | Stake | Since | |
|---|---|---|---|
Fresenius Medical Care Holdings, Inc. | at least 4.9%−1.9 pts (filed with 1 related holder) | 14 August 2026 | |
Davidson Kempner Capital Management LP Passive investor | at least 4.7% (filed with 3 related holders) | 12 June 2026 | |
BlackRock, Inc. Passive investor | Sold down below 5% | 30 June 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 3 insiders bought $90,160 of shares on the open market. 2 sold $82,597, $82,597 of it under preset trading plans.
- Jones Keith AnthonyDirectorBought
- Date
- 14 September 2026
- Shares
- 10,000
- Price
- $0.56
- Value
- $5,620
- Jones Keith AnthonyDirectorBought
- Date
- 20 August 2026
- Shares
- 10,000
- Price
- $0.69
- Value
- $6,930
- Jones Keith AnthonyDirectorBought
- Date
- 17 August 2026
- Shares
- 30,000
- Price
- $0.59
- Value
- $17,820
- Sebelius KathleenDirectorBought
- Date
- 19 May 2026
- Shares
- 56,818
- Price
- $0.88
- Value
- $50,000
- Parikh Shamik JChief Medical OfficerSoldunder a preset trading plan
- Date
- 18 May 2026
- Shares
- 45,887
- Price
- $0.90
- Value
- $41,298
- Sander Dale A.CFO and Chief Corp. Dev. OffSoldunder a preset trading plan
- Date
- 18 May 2026
- Shares
- 45,887
- Price
- $0.90
- Value
- $41,298
- Constantino Michael T.DirectorBought
- Date
- 18 May 2026
- Shares
- 11,000
- Price
- $0.89
- Value
- $9,790
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 14 September 2026 | Jones Keith Anthony Director | Bought | 10,000 | $0.56 | $5,620 |
| 20 August 2026 | Jones Keith Anthony Director | Bought | 10,000 | $0.69 | $6,930 |
| 17 August 2026 | Jones Keith Anthony Director | Bought | 30,000 | $0.59 | $17,820 |
| 19 May 2026 | Sebelius Kathleen Director | Bought | 56,818 | $0.88 | $50,000 |
| 18 May 2026 | Parikh Shamik J Chief Medical Officer | Sold under a preset trading plan | 45,887 | $0.90 | $41,298 |
| 18 May 2026 | Sander Dale A. CFO and Chief Corp. Dev. Off | Sold under a preset trading plan | 45,887 | $0.90 | $41,298 |
| 18 May 2026 | Constantino Michael T. Director | Bought | 11,000 | $0.89 | $9,790 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Humacyte’s filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 27 Mar 2026, plus the 10-Q filed 10 Nov 2026 and 10 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern.”
Show the full paragraph
As of September 30, 2026 , the Company had available cash and cash equivalents of $ 64.5 million. The Company will not have sufficient liquidity to fund its operations beyond one year from the issuance of these condensed consolidated financial statements if the Company is unable to generate sufficient cash flows from commercial sales on a timely basis and/or obtain additional capital. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The future viability of the Company is dependent on its ability to generate cash flows from the sale of Symvess and raise additional capital to finance its operations. As further disclosed in Note 10, Commitments and Contingencies, in May 2026, the Company implemented a plan to reduce its workforce by approximately 45 employees, defer additional planned new hires, and reduce other operating expenses. These reductions have been implemented thoughtfully, and the Company has retained key personnel, resources, and initiatives to meet its key corporate goals and milestones. The Company plans to seek additional funding through private or public equity financings, debt financings, debt refinancings or restructurings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements. Adequate additional capital may not be available to the Company when
From the 10-Q filed 10 November 2026, Part I, Item 1. Financial Statements. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
- It carries a lot of debt: 20.9× its equity.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.